Compounds > tazobactam
Page last updated: 2024-09-03

tazobactam and Cystic Fibrosis

tazobactam has been researched along with Cystic Fibrosis in 26 studies

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (3.85)18.2507
2000's1 (3.85)29.6817
2010's16 (61.54)24.3611
2020's8 (30.77)2.80

Authors

AuthorsStudies
Güler, N; Süleyman, A; Tamay, Z1
Böhringer, N; Horst, J; Hübner, J; Kappler, M; Kolberg, L; Kresna, IDM; Liu, Y; Marner, M; Mettal, U; Meyer-Bühn, M; Mihajlovic, S; Schäberle, TF; von Both, U; Wang, L1
Faurholt-Jepsen, D; Jensen, PØ; Johansen, HK; Katzenstein, TL; Kolpen, M; Pressler, T; Qvist, T1
Demuyser, T; Echahidi, F; Olbrecht, M; Peeters, C; Piérard, D; Vandamme, P; Wybo, I1
Abbott, IJ; Chang, CC; Dennison, A; Kostoulias, X; Peleg, AY; Spelman, DW; Wisniewski, J; Zisis, H1
Caverly, LJ; Huang, DB; Kalikin, LM; LiPuma, JJ; Spilker, T; Stillwell, T; Young, C1
Ang, JY; Arrieta, AC; Feng, EH; Johnson, MG; Larson, KB; Rhee, EG; Rizk, ML; Yu, B; Zhang, Z1
Cohen, L; Finklea, JD; Jain, R; Nolan, PJ; Smith, TT1
Baccani, I; Bartalesi, F; Bartoloni, A; Borchi, B; Bresci, S; Cavallo, A; Ottino, L; Rossolini, GM1
Blasi, F; Downey, DG; Elborn, JS; Gramegna, A; Millar, BC; Moore, JE1
Finklea, JD; Hollaway, R; Jain, R; Le, J; Lee, F; Lowe, K1
Jones, AL; Lee, AC1
De Wachter, E; Echahidi, F; Herpol, M; Peeters, C; Piérard, D; Van Dalem, A; Vandamme, P; Wybo, I1
Floch, P; Gaudru, C; Guet-Revillet, H; Massip, C; Mathieu, C; Miaut, V; Oswald, E; Segonds, C1
Di Bonaventura, G; Fiscarelli, E; Gherardi, G; Linardos, G; Pompilio, A1
Aitken, E; Gould, IM; Hijazi, K; Joshi, C; Oggioni, MR; Zamudio, R1
Baklouti, S; Concordet, D; Gandia, P; Guet-Revillet, H; Mane, C; Massip, C; Murris, M1
Ann Justo, J; Bookstaver, PB; Elizabeth Davis, S; Foster, R; Gould, A; Ham, J; Hucks, J; Nicolau, DP1
Aghazadeh, M; Hojabri, T; Hojabri, Z; Mahdian, R; Nahaei, MR; Pajand, O; Pirzadeh, T; Rahmati, M1
McClain, D; Vickery, SB; Wargo, KA1
Cies, JJ; Kuti, JL; Monogue, ML; Muhlebach, M; Nicolau, DP; Pettit, RS1
Abdel-Haq, N; Ang, JY; Nicolau, DP; Satlin, MJ; Thabit, AK; van Duin, D; Zhu, F1
Brockhurst, MA; Davies, EV; James, CE; Winstanley, C1
Compain, F; Grohs, P; Kaibi, I; Lavollay, M; Mainardi, JL; Morand, P; Podglajen, I; Taieb, G1
Jones, RN; Mutnick, AH; Turner, PJ1
Giwercman, B; Høiby, N; Lambert, PA; Rosdahl, VT; Shand, GH1

Reviews

1 review(s) available for tazobactam and Cystic Fibrosis

ArticleYear
Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
    Paediatric respiratory reviews, 2018, Volume: 27

    Topics: Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome

2018

Trials

2 trial(s) available for tazobactam and Cystic Fibrosis

ArticleYear
Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
    Pediatric pulmonology, 2020, Volume: 55, Issue:8

    Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Gram-Negative Bacterial Infections; Humans; Male; Tazobactam

2020
Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:11

    Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Lung; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Patient Safety; Penicillanic Acid; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Tazobactam

2016

Other Studies

23 other study(ies) available for tazobactam and Cystic Fibrosis

ArticleYear
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
    Pediatric pulmonology, 2022, Volume: 57, Issue:11

    Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination

2022
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
    Microbiology spectrum, 2023, 02-14, Volume: 11, Issue:1

    Topics: Adolescent; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2023, Volume: 131, Issue:8

    Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporinase; Cephalosporins; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
    Antimicrobial agents and chemotherapy, 2023, 07-18, Volume: 67, Issue:7

    Topics: Achromobacter; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Tazobactam

2023
Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia.
    Pathology, 2023, Volume: 55, Issue:5

    Topics: Adult; Anti-Bacterial Agents; Australia; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
    Antimicrobial agents and chemotherapy, 2019, 12-20, Volume: 64, Issue:1

    Topics: Achromobacter; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Burkholderia; Cystic Fibrosis; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Stenotrophomonas; Stenotrophomonas maltophilia; Tazobactam

2019
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Diagnostic microbiology and infectious disease, 2021, Volume: 99, Issue:2

    Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam

2021
Ceftolozane/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021, Volume: 40, Issue:10

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Humans; Italy; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam; Young Adult

2021
In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
    Journal of global antimicrobial resistance, 2018, Volume: 14

    Topics: Achromobacter denitrificans; Adult; beta-Lactamase Inhibitors; Burkholderia cenocepacia; Cephalosporins; Colistin; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Sputum; Stenotrophomonas maltophilia; Tazobactam

2018
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
    Diagnostic microbiology and infectious disease, 2018, Volume: 92, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam

2018
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:9

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Burkholderia cepacia complex; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Humans; Microbial Sensitivity Tests; Sulfamethoxazole; Tazobactam; Trimethoprim

2018
In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    The Journal of antimicrobial chemotherapy, 2019, 02-01, Volume: 74, Issue:2

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactams; Burkholderia cepacia complex; Burkholderia gladioli; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Tazobactam

2019
Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Diagnostic microbiology and infectious disease, 2019, Volume: 94, Issue:3

    Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Young Adult

2019
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    International journal of antimicrobial agents, 2019, Volume: 53, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Scotland; Tazobactam; Whole Genome Sequencing

2019
Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients
    The Journal of antimicrobial chemotherapy, 2019, 10-01, Volume: 74, Issue:10

    Topics: Azabicyclo Compounds; Burkholderia cepacia complex; Burkholderia gladioli; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Humans; Tazobactam

2019
Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, Apr-08, Volume: 76, Issue:8

    Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Infusions, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome

2019
Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2014, Volume: 24

    Topics: Amikacin; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Burns; Cephalosporinase; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2014
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Pharmacotherapy, 2016, Volume: 36, Issue:10

    Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome

2016
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:10

    Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2016
Evolutionary diversification of Pseudomonas aeruginosa in an artificial sputum model.
    BMC microbiology, 2017, 01-05, Volume: 17, Issue:1

    Topics: Bacteriophages; beta-Lactamases; Biodiversity; Biofilms; Biological Evolution; Culture Media; Cystic Fibrosis; Drug Resistance, Microbial; Penicillanic Acid; Phenotype; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam

2017
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:4

    Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tazobactam; Thienamycins

2017
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:3

    Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins

2002
Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains.
    The Journal of antimicrobial chemotherapy, 1990, Volume: 26, Issue:2

    Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Child; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Male; Penicillanic Acid; Pseudomonas aeruginosa; Sputum; Tazobactam

1990